Biopotency and efficacy of a FVIII gene therapy construct in hemophilia A mice

被引：0

作者：

Hoellriegl, Werner ^{[1
]}

Weiller, Markus ^{[1
]}

Kopic, Alexandra ^{[1
]}

Gritsch, Herbert ^{[1
]}

Gangadharan, Bagirath ^{[2
]}

Falkner, Falko G. ^{[2
]}

Monahan, Paul E. ^{[3
]}

Rottensteiner, Hanspeter ^{[1
]}

Scheiflinger, Edrich ^{[1
]}

Turecek, Marietta ^{[1
]}

机构：

[1] Baxalta Innovat GmbH, Vienna, Austria

[2] Baxalta Innovat Gmbh, Orth Donau, Vienna, Austria

[3] Baxalta US Inc, Northern Illinois, IL USA

来源：

HAEMOPHILIA | 2016年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：34 / 34

页数：1

共 50 条

[31] FVIII GENE VARIATIONS IN HEMOPHILIA A PATIENTS OF SOUTHWEST CHINA
Diao, G.
Ma, L.
Liu, Z.
Sun, P.
Lin, F.
Li, C.
Xiao, X.
VOX SANGUINIS, 2011, 101 : 111 - 111
[32] In Vivo Expansion of Treg Cells Prevents Anti-FVIII Antibody Production Following FVIII Protein Replacement Therapy in Hemophilia A Mice
Liu, Chao-Lien
Ye, Peiqing
Lin, Jaqueline
Miao, Carol H.
BLOOD, 2011, 118 (21) : 15 - 15
[33] Targeting FVIII Expression to Platelets for Hemophilia A Gene Therapy Does Not Bare an Apparent Thrombosis Risk
Baumgartner, Christina K.
Mattson, Jeremy G.
Weiler, Hartmut
Shi, Qizhen
Montgomery, Robert R.
BLOOD, 2015, 126 (23)
[34] Targeted FVIII expression under the control of its native promoter for hemophilia A gene and cell therapy
Zanolini, D.
Merlin, S.
Fama, R.
Borroni, E.
Bruscaggin, V.
Zucchelli, S.
Follenzi, A.
HUMAN GENE THERAPY, 2016, 27 (11) : A147 - A147
[35] Quantification of Human FVIII and Estimation of Its Molecular Weight: Potential Applications in Gene Therapy for Hemophilia A
Mahimkar, Rajeev
Carter, Barrie
Vehar, Gordon
MOLECULAR THERAPY, 2016, 24 : S66 - S67
[36] Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A
Cai, Yuanhua
Shi, Qizhen
FRONTIERS IN IMMUNOLOGY, 2020, 11
[37] Transcriptional activity. of recombinant: AAV-FVIII vectors or gene therapy of Hemophilia A.
Kelly, EJ
Jacobson, DR
Dekker, SL
Godwin, SG
Lippa, MS
Lustig, KH
Rogers, LC
SAndalon, Z
Stepan, TM
Thompson, SA
Burstein, H
Peluso, RW
Dorner, AJ
Lynch, CM
BLOOD, 2002, 100 (11) : 485B - 485B
[38] Hemophilia A gene therapy in mouse and dog models using an AAV-FVIII vector.
Couto, L
Scallan, C
Jiang, HY
Qian, XB
Patarroyo-White, S
Parker, A
Liu, TY
Chen, HF
Powell, S
Wright, F
Tinlin, S
Webster, S
Lillicrap, D
Arruda, V
High, K
Kay, M
McClelland, A
BLOOD, 2002, 100 (11) : 117A - 117A
[39] Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A
El-Akabawy, Nadia
Rodriguez, Martin
Ramamurthy, Ritu
Rabah, Andrew
Trevisan, Brady
Morsi, Alshaimaa
George, Sunil
Shields, Jordan
Meares, Diane
Farland, Andrew
Atala, Anthony
Doering, Christopher B.
Spencer, H. Trent
Porada, Christopher D.
Almeida-Porada, Graca
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2020, 17 : 465 - 477
[40] FVIII activity following FVIII protein infusion or FVIII gene transfer predicts the bleeding risk in hemophilia A rats
Lovgren, Karin M.
Larsen, Malte S.
Zintner, Shannon M.
Small, Juliana C.
Kjelgaard-Hansen, Mads
Hager, Mattias
Petersen, Maj
Wiinberg, Bo
Margaritis, Paris
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (07) : 1586 - 1597

← 1 2 3 4 5 →